MiRNA expression profile in serum of osteoarthritis patients

Dariusz Szala 3*, Joanna Czech 1,2*, Marzena Skrzypa 1,2*, Marta Kopanska 1,2,
Dorota Hanf-Osetek 3, Krzysztof Gargasz 4, Grzegorz Guzik 6,
Slawomir Snela 3,5, Izabela Zawlik 1,2**

1Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Poland;
2Department of Genetics, Chair of Molecular Medicine, Faculty of Medicine, University of Rzeszow, Poland;
3Department of Orthopaedic and Traumatology, University Hospital No 2, Rzeszow, Poland;
4Data Analysis Laboratory, Centre for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Poland;
5Institute of Physiotherapy, Faculty of Medicine, University of Rzeszow, Poland
6Department of Oncological Orthopaedics, Specialist Hospital in Brzozów – Podkarpacie Oncological Centre, Poland
Abstract

Introduction: Osteoarthritis (OA) is the most common form of arthritis that affects millions of people worldwide. Despite advances in medicine, OA still remains incurable. Scientists are still seeking candidates for biomarker-based risk stratification and the early detection of disease. Measurement of miRNAs in the serum may become a powerful tool in the development of diagnostic biomarker.

Purpose: The aim of this study was to examine the expression profiles of 20 miRNAs in the serum of patients with OA.

Methods: We used RT-qPCR method to measure the expression profile of selected miRNAs.

Results: Six miRNAs showed differential expression between OA and normal serum samples. miR-146a-5p and miR-98-5p were significantly upregulated (P < 0.05), while miR-222-3p, miR-22-3p, miR-27a-3p and miR-93-5p were downregulated (P < 0.05) compared to the control group. To the best of our knowledge, this is the first work that shows that expression of these six miRNAs is different between serum OA samples and
healthy controls. However, we did not find any statistically significant relationship between the miRNAs expression and clinical characteristics.

**Conclusions:** Our findings suggest that miRNAs can be used as potential biomarkers for OA, but further research is needed to assess the usefulness of serum miRNAs in miRNA-based prognostic and therapeutic approaches.

**Key words:** expression; miRNA; osteoarthritis; serum

1. **Introduction**

Degenerative joint disease, also known as osteoarthritis (OA), is the most common chronic disease of the musculoskeletal system. It develops as a result of impaired quality and quantity of articular cartilage, whose task is to cushion the movements of the joint and other articular surfaces [1]. OA leads to a deterioration of the disability and quality of life. Many risk factors affect the pathogenesis, presentation and prognosis of OA. These include systematic risk factors such as age, gender and hormones, race/ethnicity, congenital/developmental conditions, genetics, diet, and also local risk factors including obesity, injury/surgery, physical activity/sport, occupation or mechanical factor [2]. Therefore, a multifactorial etiology of OA can be considered the product of an interplay of local and systemic factors. Until recently, OA was considered a sign of aging and simple "wear and tear" of the articular cartilage. Results from several studies have shown that age is one of the strongest risk factors for OA [3, 4], but joint injury and obesity have been found to be strongly associated with the disease [5]. However, for past several years, OA is the subject of increasing interest for scientists and doctors, as also applies to young adults [6, 7]. OA is still in the realm of researches and orthopaedic surgeons who are trying to find effective treatment for inhibiting its development. Because current knowledge about OA is incomplete, there is a pressing
need to find molecular biomarkers for early detection and in consequence prevention of this disease.

There are promising potential biomarkers for OA, e.g. biochemical, genetic and epigenetic, which are still under investigation and in the near future could be used in clinical decision making [8]. The special attention is deserved by miRNAs, which are one of the forms of RNA and are involved in a number of physiological and pathological processes [9]. MicroRNAs (miRNAs) are a family of non-coding, endogenous regulatory molecules, produced from double-stranded precursors known as pre-miRNAs. They consist normally of 21-23 single-nucleotides. The function of miRNAs is associated with posttranscriptional regulation of the expression of numerous genes by binding to specific sequence within target messenger RNA (mRNA). A single molecule miRNA can simultaneously control the expression of hundreds of target genes [10]. It is estimated that miRNAs account for 1-5% of the human genome and more than 30% of protein-coding genes in human cells are regulated by these molecules [11]. Numerous scientific reports have shown that miRNAs play a very important role in a number of physiological processes in humans such as cell growth, proliferation, cell differentiation, apoptosis but also in oncogenesis [9]. In fact, their expression levels are dysregulated in response to pathological abnormalities, thereby resulting in the pathogenesis of many human diseases [12] including degenerative diseases, such as OA [13]. Therefore, we aimed to identify the expression pattern of selected miRNAs in the serum of patients with OA in comparison with healthy controls that can predict the risk of early development of disease and in the future can be used as potential clinical applications.

2. Material and methods

2.1. Patients

Ethical approval for this study was granted by the Bioethical Committee of the Medical Faculty of Rzeszow University (number: 5/01/2014). Study subjects were recruited in The Clinical Department of Orthopedics and Traumatology Adults and Children at the Clinical Regional Hospital No. 2 for them. St. Jadwiga in Rzeszow. Patients were diagnosed according to the American College of Rheumatology (ACR)
criteria for this disease. Informed consent was obtained from all patients who took the part in the study. We included into the study serum samples of 36 OA patients (sex: 15 Females and 21 Males, mean age: 64±16) and 3 healthy controls without OA (sex: 1 Females and 2 Males, mean age: 55±26). Among the patients 12 were classified as early and 24 as late stage of the disease. Every subject was interviewed to obtain the individuals’ complete clinical history including general information, previous injuries, BMI, occupational or sports activities, and clinical manifestations of OA.

2.2. RNA extraction from serum

Serum samples were centrifuged twice at 3000 x rpm for 5 minutes and stored in a -80°C freezer until analysis. For miRNA qPCR analyses, total RNA (including miRNAs) was isolated from serum using the miRCURY™ RNA isolation kit – biofluids (Exiqon, Vedbaek, Denmark) following the manufacturer’s suggested protocol.

2.3. Reverse transcription and quantification of miRNAs by real-time PCR

Based on previous reports in the literature and the miRNA databases we selected 20 miRNAs (14-30). In all 39 serum samples (3 from healthy control group and 36 from patients with OA) we analyzed 20 miRNAs: let-7e-5p, miR-101-3p, miR-127-5p, miR-130a-3p, miR-138-5p, miR-146a-5p, miR-16-5p, miR-193b-3p, miR-199a-3p, miR-210-3p, miR-21-5p, miR-222-3p, miR-22-3p, miR-27a-3p, miR-27b-3p, miR-335-5p, miR-454-3p, miR-9-5p, miR-98-5p and miR-93-5p. For normalization of the data, we have applied three miRNAs: miR-423-5p, miR-103a-3p and miR-191-5p as those were found by Exiqon (Copenhagen, Denmark) to be good reference genes in serum and plasma samples and are proved to be the most stable normalizers. As technical controls, an RNA spike-in (UniSp6) was used for the quality control of the RNA isolation and cDNA synthesis [31]. For the reverse transcription and quantitation of miRNAs by real-time PCR, reagents from Exiqon (Copenhagen, Denmark) were used. Reverse transcription and real-time PCR were performed like as described previously [31]. Briefly, the miRCURY LNA™ Universal RT microRNA PCR, Polyadenylation and
cDNA synthesis kit was used for reverse transcription 2 μl of RNA samples into cDNA in 10 μl reactions (a single reaction step). cDNA was diluted 50x and assayed in 10 μl PCR reactions in a protocol designed for miRCURY LNA™ Universal RT microRNA PCR; each microRNA was assayed once by qPCR on the microRNA Ready-to-Use PCR, Custom Pick and Mix using ExiLENT SYBR® Green master mix. The target cDNA sequences were amplified by qRT-PCR in 384-well plates in a LightCycler® 480 Real-Time PCR System (Roche, Basel, Switzerland). We analyzed the amplification curves using the Roche LC software both for determination of Cp (by the 2nd derivative method) and melting curve analysis.

2.4. Data analysis

For data analysis we used the methods used in Valassi et al. study. To calculate amplification efficiency algorithms similar to the LinReg software were used. Assays were inspected for distinct melting curves and Tm to be within assays known specifications. Analysed assays were detected with 3 Cqs less than the negative control, and with Cq≤37 (data that did not pass these criteria were omitted from further analysis). In the study Cq was calculated as the 2nd derivative. According to NormFinder, the average of the tests found in all samples turned out to be the best normalizer (miR-103a-3p, miR-423-5p and miR-191-5p) [33]. We calculated the normalizes Cq using the following formula: normalized Cq = average Cq (n=93) – assay Cq (sample).

Statistical analysis

All statistical analyses were performed using Statistica 12.5 PL software (Statsoft, Poland). The distribution of variables was tested with Shapiro-Wilk test and Kolmogorov-Smirnov test with Lilkefors’ correction. For all non-normal distributed data, we used non-parametric test. P values less than 0.05 were considered to be statistically significant.

3. Results

From previously reported miRNA studies we selected 20 miRNAs which have been described as being involved in the pathogenesis of OA [14-30]. miRNAs for the
study were generated by extracting total RNA from serum of healthy donors (n=3) and OA patients (n=36). qRT-PCR technique was used to identify the expression profiles of selected miRNAs. Five miRNAs (miR-127-5p, miR-138-5p, miR-193b-3p, miR-21-5p and miR-9-5p) have been excluded from the analysis because of the frequent failure to detect the samples. The remaining fifteen (let-7e-5p, miR-101-3p, miR-130a-3p, miR-146a-5p, miR-16-5p, miR-199a-3p, miR-210-3p, miR-222-3p, miR-22-3p, miR-27a-3p, miR-27b-3p, miR-335-5p, miR-454-3p, miR-98-5p and miR-93-5p) were tested using U Mann-Whitney test in order to demonstrate the differences between OA groups and the control. We found that expression of miR-146a-5p and miR-98-5p was increased significantly, while the expression of miR-222-3p, miR-22-3p, miR-27a-3p and miR-93-5p was decreased significantly in the serum of patients with OA (Fig. 1).

![Differential expression of serum miRNAs in osteoarthritis](image)

Fig. 1. Differential expression of serum miRNAs in osteoarthritis. *Statistically significant differences between the two groups (p<0.05)

The heat map diagram shows the result of differentially expressed miRNAs in patients with OA and healthy controls. The relative miRNA expression levels were calculated based on the two-way hierarchical clustering of miRNAs and samples. The distance between two clusters was defined as the average distance between all pairs of the two clusters’ members (average linkage), and Pearson correlation. Hierarchical
clustering was done in R (version 3.2.3) using scripts from Bioconductor (3.3). The colour scale illustrates the relative level of miRNA expression: green color represents downregulation, red color represents upregulation (Fig. 2).

Fig. 2. Unsupervised hierarchical clustering of the serum differentially expressed miRNAs in healthy controls and patients with osteoarthritis. The clustering is performed on all samples. Each row represents one miRNA, and each column represents one sample. The miRNA clustering tree is shown on the left. The normalized (dCq) values have been used for the analysis. The colour scale illustrates the relative level of miRNA expression: red color represents an expression level above mean, green color represents expression lower than the mean.
We did not find any statistically significant relationship between the expression of miRNAs and clinical characteristics. We have also observed no significant correlation between miRNA expression level between early and late stages of OA.

4. Discussion

OA arises as a result of mechanical and biological degenerative changes. These lead to instability and changes in the balance between the processes of degradation and synthesis of structures of cartilage and subchondral bone [34]. In recent years, reports of research findings have revealed various roles for specific miRNAs in physiological processes but also in OA development [19, 35, 36]. OA is an irreversible process that often results in a physical disability, therefore there is a need to find effective treatment for inhibiting its development.

There are some evidences indicating that miRNAs can be useful as OA biomarkers. miRNA in serum or plasma hold great promise as minimally invasive diagnostic biomarkers for a wide range of diseases [37]. miRNAs have wide-ranging biological potential, are limited in numbers and are relatively stable in serum/plasma. It has been shown that miRNAs have potential as predictor for severe knee or hip OA [14, 38]. However, there is still a limited number of serum miRNA expression profiling studies in OA. Therefore, in the present study we determined the expression profile of selected miRNAs in serum of OA patients. We have found that expression of miR-146a-5p and miR-98-5p was increased significantly, while miR-222-3p, miR-22-3p, miR-27a-3p and miR-93-5p was decreased significantly in serum of patients with OA in comparison with healthy subjects. Moreover, literature data indicates that all of these miRNAs are associated with promotion or progression of OA [19, 25, 36, 39-41]. In this study we did not found any statistically significant relationship between the expression of selected miRNA and clinical characteristics.

miR-146a is one of the first identified miRNAs, which was differentially expressed in OA cartilage. Li et al. showed that in OA in both the homeostasis of the joint cells and the severity of pain symptoms, miR-146a plays an important role by maintaining the balance between the inflammatory response and expression of pain-associated factors in different joint tissue [42]. In OA, inflammation of the synovium results in the
production of tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) that are produced by mononuclear cells activated synoviocytes and articular cartilage and are involved in the pathogenesis of OA. This may cause the cascade of inflammatory factors that lead to chronic inflammation of the synovium [43]. Nakasa et al. demonstrated that in cartilage with low Mankin grade miR-146a is strongly expressed, and its expression is decreasing proportionally with the level of matrix metalloproteinase 13 (MMP-13) expression. [44]. Moreover, the study by Taganov et al. reported that in early-stage OA, miR-146a expression in cartilage tissue can be activated by IL-1β, concurrently with the onset of degenerative changes, which can be significant in repression of catabolic factors like interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6) [44,45]. In late stages of OA, decreased level of miR-146a expression in OA cartilage has been observed in comparition of early stage of OA. It suggests that cartilage degradation might progress due to loss of miR-146a functioning as a repressor of catabolic signals [19]. Okuhara et al. observed that expression levels of miR-146a, -155, -181a, and -223 in PBMCs (Peripheral Blood Mononuclear Cells) of OA patients were significantly higher than those found in healthy controls, suggesting these miRNAs are related to the pathogenesis of OA. Moreover, in the early stages of OA, miR-146a and 223 expressions were significantly higher than they were at later stages [41]. miR-146a may also be associated with OA pathogenesis by increasing vascular endothelial growth factor (VEGF) levels and by impairing the transforming growth factor-beta (TGF-β) signalling pathway through targeted inhibition of mothers against decapentaplegic homolog 4 (SMAD4) in cartilage [46].

Jones et al. identified that miR-9, miR-98 were upregulated in OA cartilage and miR-146 was downregulated in both OA bone and cartilage tissue. Moreover, overexpression of these miRNAs in isolated human chondrocytes reduced IL-1β induced TNF-α production, what suggests that they mediate pathways regulated inflammatory response [40]. It is known that osteoblasts also participate in the inflammation process. It has been reported that proinflammatory cytokine, leptin, induces production of oncostatin M in osteoblast by downregulating miR-93 through the Act signalling pathway [39].
Literature data indicates that also miR-22 can be involved in inflammatory networks in OA. In chondrocytes, miR-22 directly regulates two target genes, peroxisome proliferator-activated receptor alpha (PPARα) and bone morphogenetic protein 7 (BMP-7), and its upregulation induced inflammatory and catabolic changes [25]. PPARα is a receptor involved in metabolism sub-network, which is connected with inflammatory process trough IL-1β, and its decreased expression was found in OA cartilage [47]. Expression of BMP-7 is also frequently decreased in osteoarthritic cartilage, whilst MBP7 overexpression induces formation of cartilage [48]. Moreover, inflammatory process could be blocked by inhibition of miR-22 in osteoarthritic chondrocytes and subsequently upregulate the expression of cartilage repair protein, aggrecan. Furthermore, upregulation of miR-22 expression was positively correlated with BMI in OA patients [25]. However, in our study there is no correlation between miR-22 expression and BMI in OA patients.

Tardif et al. suspect that MMP-13, as well as insulin-like growth factor-binding protein 5 (IGFBP-5), are likely indirect targets of miR-27a in human chondrocytes [36]. MMP-13 is well known to be upregulated in OA and to play a major role in the pathophysiological process of disease [49]. Findings from several studies have shown that the IGFBP-5 expression level was dysregulated in human OA cartilage, chondrocytes or subchondral bone osteoblast [50-52]. MMP13 is also regulated by miR-222. In Song et al. study, the over-expression of miR-222 significantly reduced the cartilage destruction in DMM-induced mice, whereas it was intensified by suppression of miR-222. RNA and protein levels of MMP-13 were decreased by the over-expression of miR-222 and increased by suppression of miR-222. The histone deacetylase 4 (HDAC-4) was also decreased by the over-expression miR-222. These data indicate that miR-222 is involved in cartilage destruction by regulating MMP-13 level and targeting HDAC-4 [24]. In addition, miR-222 may be involved in an articular cartilage mechanotransduction pathway. It has been shown that expression pattern of this miRNA in articular cartilage was higher in the weight-bearing anterior medial condyle as compared with the posterior nonweight-bearing medial condyle [53].
5. Conclusions

Taken together, scientists have so far identified and described a variety of risk factors, molecular mechanisms of pathological processes that are responsible for the creation and development of OA. Despite this, OA is still an incurable disease. Due to the complexity of pathological processes occurring in the joints it is difficult to develop an effective drug therapy. miRNAs found in body fluid such as serum in a stable form have the potential to be a diagnostic and prognostic biomarker of various diseases including OA. It is important to diagnose OA earlier and to start treatment to prevent joint destruction so the distinctive profile of changes in the expression levels of miRNAs can be helpful in early diagnosis. miRNAs are also a promising target for assessment of prognosis and selection of potential therapeutic intervention in OA. We have found an alteration in expression of six miRNAs including miR-146a-5p, miR-98-5p, miR-222-3p, miR-22-3p, miR-27a-3p and miR-93-5p, but we did not find any statistically significant relationship between clinical data and the expression of selected miRNA. Therefore, further research is needed to assess the usefulness of serum miRNAs in miRNA-based prognostic and therapeutic approaches.

Abbreviations

BMP-7 – bone morphogenetic protein 7
Cq – quantification cycle
HDAC-4 – histone deacetylase 4
IGFBP-5 – insulin-like growth factor-binding protein 5
IL-1β – interleukin 1 beta
IRAK1 – interleukin-1 receptor-associated kinase 1
MMP-13 – matrix metalloproteinase 13
OA – osteoarthritis
PPARα – peroxisome proliferator-activated receptor alpha
SMAD4 – mothers against decapentaplegic homolog 4
TGF-β – transforming growth factor-beta
TNFα – tumor necrosis factor alpha
TRAF6 – TNF receptor-associated factor 6
VEGF – vascular endothelial growth factor
Conflicts of interest
The authors declare no conflict of interest with regard to this study.

Declarations
Ethics approval and consent to participate
The investigation process was approved by the Bioethical Committee of the Medical Faculty 270 of Rzeszow University (number: 5/01/2014). Written informed consent was obtained.

Consent for publication
Not applicable.

Availability of data and materials
All data and materials were presented in the main paper.

Competing interests
The authors declare that they have no competing interests.

Funding
This study was supported by funds provided by the University of Rzeszow. The study was performed as part of the project ‘Centre for Innovative Research in Medical and Natural Sciences’ realized by University of Rzeszow, co-financed within Regional Operational Programme for the Podkarpackie Province for the years 2007-2013, contract number UDA-RPPK.01.03.00-18-004/12-00. The funds have been used in analysis and interpretation of data.

Authors’ contributions
D. Sz.: material and data collection, data interpretation, manuscript preparation, literature search
J. C.: study design, material and data collection, data interpretation, manuscript preparation, literature search
M. S.: material and data collection, data interpretation, manuscript preparation, literature search
M. K.: material and data collection
D. H.-O.: material and data collection
K. G.: statistical analysis
G. G.: manuscript preparation, literature search
S. S.: material and data collection, data interpretation
I. Z.: study design, data interpretation, manuscript preparation, literature search. I. Z. supervised the study.

All authors contributed to data interpretation and manuscript preparation and approved the final version submitted

Acknowledgments
We thank the staff from the Department of Orthopaedic and Traumatology, University Hospital No 2, Rzeszow and the patients for participating in the study. We would also like to acknowledge the Laboratory of Molecular Biology, Centre for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow and Department of Genetics, Chair of Molecular Medicine, Faculty of Medicine, University of Rzeszow.

References
[1] Goldring MB, Goldring SR. Osteoarthritis. Journal of cellular physiology 2007;213(3):626-34.
[2] Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010;26(3):355-69.
[3] Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41(8):1343-55.
[4] Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58(1):26-35.
Factors associated with osteoarthritis of the hip and knee in Hong Kong Chinese: obesity, joint injury, and occupational activities. Am J Epidemiol 2000;152(9):855-62.

Amoako AO, Pujalte GG. Osteoarthritis in young, active, and athletic individuals. Clinical medicine insights Arthritis and musculoskeletal disorders 2014;7:27-32.

Roos EM. Joint injury causes knee osteoarthritis in young adults. Current opinion in rheumatology 2005;17(2):195-200.

Goldring MB, Otero M. Inflammation in osteoarthritis. Current opinion in rheumatology 2011;23(5):471-8.

Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 2010;1803(11):1231-43.

Satoh J, Tabunoki H. Comprehensive analysis of human microRNA target networks. BioData Min 2011;4:17.

Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics 2010;11(7):537-61.

Li M, Marin-Muller C, Bharadwaj U, Chow KH, Yao Q, Chen C. MicroRNAs: control and loss of control in human physiology and disease. World journal of surgery 2009;33(4):667-84.

Diaz-Prado S, Cicione C, Muinos-Lopez E, Hermida-Gomez T, Oreiro N, Fernandez-Lopez C, et al. Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes. BMC musculoskeletal disorders 2012;13:144.

Beyer C, Zampetaki A, Lin NY, Kleyer A, Perricone C, Iagnocco A, et al. Signature of circulating microRNAs in osteoarthritis. Annals of the rheumatic diseases 2015;74(3):e18.

Dai L, Zhang X, Hu X, Liu Q, Man Z, Huang H, et al. Silencing of miR-101 Prevents Cartilage Degradation by Regulating Extracellular Matrix-related Genes in a Rat Model of Osteoarthritis. Molecular therapy : the journal of the American Society of Gene Therapy 2015;23(8):1331-40.
[16] Park SJ, Cheon EJ, Lee MH, Kim HA. MicroRNA-127-5p regulates matrix metalloproteinase 13 expression and interleukin-1beta-induced catabolic effects in human chondrocytes. Arthritis and Rheumatism 2013;65(12):3141-52.

[17] Li ZC, Han N, Li X, Li G, Liu YZ, Sun GX, et al. Decreased expression of microRNA-130a correlates with TNF-alpha in the development of osteoarthritis. International journal of clinical and experimental pathology 2015;8(3):2555-64.

[18] Seidl CI, Martinez-Sanchez A, Murphy CL. Derepression of MicroRNA-138 Contributes to Loss of the Human Articular Chondrocyte Phenotype. Arthritis Rheumatol 2016;68(2):398-409.

[19] Yamasaki K, Nakasa T, Miyaki S, Ishikawa M, Deie M, Adachi N, et al. Expression of MicroRNA-146a in osteoarthritis cartilage. Arthritis and Rheumatism 2009;60(4):1035-41.

[20] Li L, Jia J, Liu X, Yang S, Ye S, Yang W, et al. MicroRNA-16-5p Controls Development of Osteoarthritis by Targeting SMAD3 in Chondrocytes. Current Pharmaceutical Design 2015;21(35):5160-7.

[21] Ukai T, Sato M, Akutsu H, Umezawa A, Mochida J. MicroRNA-199a-3p, microRNA-193b, and microRNA-320c are correlated to aging and regulate human cartilage metabolism. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 2012;30(12):1915-22.

[22] Zhang D, Cao X, Li J, Zhao G. MiR-210 inhibits NF-kappaB signaling pathway by targeting DR6 in osteoarthritis. Scientific Reports 2015;5:12775.

[23] Zhang Y, Jia J, Yang S, Liu X, Ye S, Tian H. MicroRNA-21 controls the development of osteoarthritis by targeting GDF-5 in chondrocytes. Experimental & Molecular Medicine 2014;46:e79.

[24] Song J, Jin EH, Kim D, Kim KY, Chun CH, Jin EJ. MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis. BBA Clinical 2015;3:79-89.

[25] Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PloS one 2008;3(11):e3740.
[26] Wang T, Xu Z. miR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochemical and biophysical research communications 2010;402(2):186-9.

[27] Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR, Haqqi TM. MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis and rheumatism 2010;62(5):1361-71.

[28] Tornero-Esteban P, Rodriguez-Rodriguez L, Abasolo L, Tome M, Lopez-Romo P, Herranz E, et al. Signature of microRNA expression during osteogenic differentiation of bone marrow MSCs reveals a putative role of miR-335-5p in osteoarthritis. BMC musculoskeletal disorders 2015;16:182.

[29] Min Z, Zhang R, Yao J, Jiang C, Guo Y, Cong F, et al. MicroRNAs associated with osteoarthritis differently expressed in bone matrix gelatin (BMG) rat model. International journal of clinical and experimental medicine 2015;8(1):1009-17.

[30] Borgonio Cuadra VM, Gonzalez-Huerta NC, Romero-Cordoba S, Hidalgo-Miranda A, Miranda-Duarte A. Altered expression of circulating microRNA in plasma of patients with primary osteoarthritis and in silico analysis of their pathways. PloS one 2014;9(6):e97690.

[31] Kopanińska M, Szala D, Czech J, et al. "MiRNA expression in the cartilage of patients with osteoarthritis." Journal of orthopaedic surgery and research 12.1 (2017): 51.

[32] Paszek S, Gabło N, Barnaś E, et al. "Dysregulation of microRNAs in triple-negative breast cancer." Ginekologia polska 88.10 (2017): 530-536.

[33] Valassi E, Garcia-Giralt N, Malouf J, et al. "Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly." Endocrine connections 8.1 (2019): 39-49.

[34] Sharma AR, Jagga S, Lee SS, Nam JS. Interplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritis. International journal of molecular sciences 2013;14(10):19805-30.

[35] Miyaki S, Sato T, Inoue A, Otsuki S, Ito Y, Yokoyama S, et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes & development 2010;24(11):1173-85.
[36] Tardif G, Hum D, Pelletier JP, Duval N, Martel-Pelletier J. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC musculoskeletal disorders 2009;10:148.

[37] Xu L, Qi X, Duan S, Xie Y, Ren X, Chen G, et al. MicroRNAs: potential biomarkers for disease diagnosis. Bio-medical materials and engineering 2014;24(6):3917-25.

[38] Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis research & therapy 2010;12(3):R86.

[39] Yang WH, Tsai CH, Fong YC, Huang YL, Wang SJ, Chang YS, et al. Leptin induces oncostatin M production in osteoblasts by downregulating miR-93 through the Akt signaling pathway. International journal of molecular sciences 2014;15(9):15778-90.

[40] Jones SW, Watkins G, Le Good N, Roberts S, Murphy CL, Brockbank SM, et al. The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and MMP13. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2009;17(4):464-72.

[41] Okuhara A, Nakasa T, Shibuya H, Niimoto T, Adachi N, Deie M, et al. Changes in microRNA expression in peripheral mononuclear cells according to the progression of osteoarthritis. Modern rheumatology / the Japan Rheumatism Association 2012;22(3):446-57.

[42] Li X, Gibson G, Kim JS, Kroin J, Xu S, van Wijnen AJ, et al. MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis. Gene 2011;480(1-2):34-41.

[43] Furuzawa-Carballeda J, Macip-Rodriguez PM, Cabral AR. Osteoarthritis and rheumatoid arthritis pannus have similar qualitative metabolic characteristics and pro-inflammatory cytokine response. Clinical and experimental rheumatology 2008;26(4):554-60.

[44] Nakasa T, Nagata Y, Yamasaki K, Ochi M, et al. "A mini-review: microRNA in arthritis." Physiological Genomics 43.10 (2011): 566-570.
[45] Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappa B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481–12486, 2006

[46] Li J, Huang J, Dai L, Yu D, Chen Q, Zhang X, et al. miR-146a, an IL-1beta responsive miRNA, induces vascular endothelial growth factor and chondrocyte apoptosis by targeting Smad4. Arthritis research & therapy 2012;14(2):R75.

[47] Watters JW, Cheng C, Pickarski M, Wesolowski GA, Zhuo Y, Hayami T, et al. Inverse relationship between matrix remodeling and lipid metabolism during osteoarthritis progression in the STR/Ort mouse. Arthritis and rheumatism 2007;56(9):2999-3009.

[48] Im HJ, Pacione C, Chubinskaya S, Van Wijnen AJ, Sun Y, Loeser RF. Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes. The Journal of biological chemistry 2003;278(28):25386-94.

[49] Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. The Journal of clinical investigation 1996;97(3):761-8.

[50] Massicotte F, Fernandes JC, Martel-Pelletier J, Pelletier JP, Lajeunesse D. Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone 2006;38(3):333-41.

[51] Iwanaga H, Matsumoto T, Enomoto H, Okano K, Hishikawa Y, Shindo H, et al. Enhanced expression of insulin-like growth factor-binding proteins in human osteoarthritic cartilage detected by immunohistochemistry and in situ hybridization. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2005;13(5):439-48.

[52] Olney RC, Tsuchiya K, Wilson DM, Mohtai M, Maloney WJ, Schurman DJ, et al. Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-II or IGFBP-4. The Journal of clinical endocrinology and metabolism 1996;81(3):1096-103.
[53] Dunn W, DuRaine G, Reddi AH. Profiling microRNA expression in bovine articular cartilage and implications for mechanotransduction. Arthritis and rheumatism 2009;60(8):2333-9.